Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2023 | -$0.12 | -$0.11 | Beat |
| Mar 28, 2023 | -$0.03 | -$0.11 | Miss |
| Dec 31, 2022 | – | -$0.10 | |
| Nov 14, 2022 | -$0.06 | -$0.12 | Miss |
| Aug 9, 2022 | -$0.13 | -$0.13 | Beat |
